<DOC>
	<DOCNO>NCT01731951</DOCNO>
	<brief_summary>This pilot clinical trial study well imetelstat sodium work treat patient primary secondary myelofibrosis myeloid malignancy . Imetelstat sodium may stop growth cancer cell block enzymes need cell growth</brief_summary>
	<brief_title>Imetelstat Sodium Treating Patients With Primary Secondary Myelofibrosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate overall response rate . SECONDARY OBJECTIVES : I . To evaluate safety tolerability imetelstat ( imetelstat sodium ) myelofibrosis ( MF ) . II . To evaluate efficacy imetelstat reduction spleen size , measure physical examination ( palpable distance leave costal margin ) . III . To evaluate efficacy imetelstat improve anemia induce red blood cell transfusion-independence previously transfusion-dependent patient ( per International Working Group Myelofibrosis Research Treatment [ IWG-MRT ] criterion ) . IV . To evaluate onset durability response define primary secondary endpoint EXPLORATORY OBJECTIVES : I . To evaluate effect imetelstat bone marrow histology , karyotype JAK2V617F allele burden II . To evaluate effect imetelstat leukocytosis , circulate blast count , circulate immature myeloid cell count thrombocytosis . OUTLINE : Patients receive imetelstat sodium intravenously ( IV ) 2 hour day 1 . Patients may continue receive imetelstat study treatment long derive clinical benefit study end . The study end patient discontinue study drug , last patient enrol treated 5 year , imetelstat commercially available United States , whichever occur first . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis one following : primary myelofibrosis ( PMF ) per revise World Health Organization ( WHO ) criteria postpolycythemia vera/essential thrombocythemia myelofibrosis ( PostET/PV MF ) per International Working Group Myeloproliferative Neoplasms Research Treatment ( IWGMRT ) criterion Highrisk Intermediate2 risk MF ( define Dynamic International Prognostic Scoring System [ DIPSSplus ] ) Life expectancy great equal ( &gt; = ) 12 week Able provide inform consent willing sign inform consent form Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 2.5 x upper limit normal ( ULN ) ( = &lt; 5 x ULN investigator 's opinion elevation due extramedullary hematopoiesis ) Serum glutamic pyruvate transaminase ( SGPT ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) ( = &lt; 5 x ULN investigator 's opinion elevation due extramedullary hematopoiesis ) Total bilirubin = &lt; 3.0 mg/dL ( direct bilirubin &lt; 1 mg/dL ) Creatinine = &lt; 3.0 mg/dL Absolute neutrophil count &gt; = 1000/microliter ( mcL ) Platelet count &gt; = 50,000/mcL Absence active treatment systemic anticoagulation baseline prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) exceed 1.5 x ULN Females childbearing potential must negative pregnancy test = &lt; 7 day prior registration , unless surgically sterile least 3 month ( i.e. , hysterectomy ) , OR postmenopausal least 12 month ( folliclestimulating hormone [ FSH ] &gt; 30 U/mL ) Females childbearing potential must agree take appropriate precaution avoid pregnancy ( least 99 % certainty ) screen end study ; permit method prevent pregnancy must communicate study subject understand confirmed Males must agree take appropriate precaution avoid father child ( least 99 % certainty ) screen followup ; permit method prevent pregnancy communicate subject understand confirm Females pregnant currently breastfeed Any chemotherapy ( e.g. , hydroxyurea ) , immunomodulatory drug therapy ( e.g. , thalidomide ) , immunosuppressive therapy , corticosteroid &gt; 10 mg/day prednisone equivalent , growth factor treatment ( e.g. , erythropoietin ) Janus kinase ( JAK ) inhibitor therapy = &lt; 14 day prior registration Subjects another active malignancy Note : patient early stage squamous cell carcinoma skin , basal cell carcinoma skin cervical intraepithelial neoplasia eligible enrollment Known positive status human immunodeficiency virus ( HIV ) Any unresolved toxicity great equal grade 2 previous anticancer therapy , except stable chronic toxicity expect resolve Incomplete recovery prior surgical procedure surgery = &lt; 4 week prior registration , exclude placement vascular access Presence acute active infection require antibiotic Uncontrolled intercurrent illness concurrent condition , Investigator 's opinion , would jeopardize safety patient compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Myeloproliferative Neoplasm</keyword>
	<keyword>Imetelstat</keyword>
	<keyword>GRN163L</keyword>
</DOC>